BAY 57-9352 is primarily investigated for its potential application in the field of medical research, particularly in the treatment of viral infections. It has shown promise as an antiviral agent, specifically targeting RNA viruses. Studies have explored its efficacy in inhibiting viral replication, making it a candidate for developing treatments against diseases caused by such viruses. Additionally, its mechanism of action, which involves interfering with viral RNA-dependent RNA polymerase, has been a focus of research to understand its broader therapeutic potential. This compound is often used in experimental settings to further elucidate its antiviral properties and to assess its safety and efficacy in preclinical models.